Thus, we first confirmed that TGF-β1 treatment was able to enhance the ovarian cancer cell EMT in vitro by assessing the tumor cell morphology and expression of EMT markers (E-cadherin and vimentin). This evidence concerns the gene TGFB1 and ovarian carcinoma.